Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSL ( (AU:CSL) ) just unveiled an update.
CSL Limited announced the cessation of 32,733 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s capital structure and could have implications for stakeholders, reflecting the company’s ongoing adjustments in managing its securities and market positioning.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$256.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma therapies, vaccines, and pharmaceuticals, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 1,179,912
Technical Sentiment Signal: Sell
Current Market Cap: A$89B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.